Duncan AE, et al. - Researchers tested the hypothesis that hyperinsulinemic normoglycemia reduces 30-day mortality and morbidity after cardiac surgery. They compared 30-day mortality, mechanical circulatory support, infection, renal or neurologic morbidity among cardiac surgical patients who received either intraoperative glycemic management with hyperinsulinemic normoglycemia, a fixed high-dose insulin and concomitant variable glucose infusion titrated to glucose concentrations of 80 to 110 mg·dl^-1; or those who received standard glycemic management,low-dose insulin infusion targeting glucose greater than 150 mg·dl^-1. Reduced postoperative mortality and morbidity were achieved with intraoperative hyperinsulinemic normoglycemia. In order to simply normalizing glucose concentrations, it may be preferable to provide exogenous glucose while targeting normoglycemia.